Pfizer tracks Real-World vaccine safety in korean population
NCT ID NCT06760208
Summary
This study aims to monitor the safety of the Prevenar 20 pneumococcal vaccine in routine medical practice in Korea. It will enroll 660 participants aged 6 weeks and older who receive the vaccine as part of their normal healthcare. Researchers will track any side effects or reactions for 28 days after vaccination to better understand the vaccine's safety profile in real-world use.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL IMMUNIZATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pfizer Korea
RECRUITINGSeoul, South Korea
Conditions
Explore the condition pages connected to this study.